S Naicker1. 1. Division of Nephrology, University of the Witwatersrand, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa. Saraladevi.Naicker@wits.ac.za
Abstract
AIMS: To review prevalence, causes and management of end-stage renal disease (ESRD) in sub-Saharan Africa (SSA). MATERIALS AND METHODS: Review of literature and data. RESULTS: Approximately 70% of the least developed countries of the world are in SSA. Rapid urbanization is occurring in many parts of the continent, contributing to overcrowding and poverty. While infections and parasitic diseases are still the leading cause of death in Africa, non-communicable diseases are coming to the forefront. There is a continuing "brain drain" of healthcare workers (physicians and nurses) from Africa to more affluent regions. There are large rural areas of Africa that have no health professionals to serve these populations. There are no nephrologists in many parts of SSA; the numbers vary from 0.5 per million population (pmp) in Kenya to 0.6 pmp in Nigeria, 0.7 pmp in Sudan and 1.1 pmp in South Africa. Chronic kidney disease affects mainly young adults aged 20 - 50 years in SSA and is primarily due to hypertension and glomerular diseases. HIV- related glomerular disease often presents late, with patients requiring dialysis. Diabetes mellitus affects 9.4 million people in Africa. The prevalence of diabetic nephropathy is estimated to be 6 - 16% in SSA. The current dialysis treatment rate is < 20 pmp (and nil in many countries of SSA), with in-center hemodialysis the modality of RRT for the majority. Transplantation is carried out in a few SSA countries: South Africa, Nigeria, Mauritius and Ghana, with most of the transplants being living donor transplants, except in South Africa where the majority are from deceased donors. CONCLUSION: Chronic kidney disease care is especially challenging in SSA, with large numbers of ESRD patients, inadequate facilities, funding and support.
AIMS: To review prevalence, causes and management of end-stage renal disease (ESRD) in sub-Saharan Africa (SSA). MATERIALS AND METHODS: Review of literature and data. RESULTS: Approximately 70% of the least developed countries of the world are in SSA. Rapid urbanization is occurring in many parts of the continent, contributing to overcrowding and poverty. While infections and parasitic diseases are still the leading cause of death in Africa, non-communicable diseases are coming to the forefront. There is a continuing "brain drain" of healthcare workers (physicians and nurses) from Africa to more affluent regions. There are large rural areas of Africa that have no health professionals to serve these populations. There are no nephrologists in many parts of SSA; the numbers vary from 0.5 per million population (pmp) in Kenya to 0.6 pmp in Nigeria, 0.7 pmp in Sudan and 1.1 pmp in South Africa. Chronic kidney disease affects mainly young adults aged 20 - 50 years in SSA and is primarily due to hypertension and glomerular diseases. HIV- related glomerular disease often presents late, with patients requiring dialysis. Diabetes mellitus affects 9.4 million people in Africa. The prevalence of diabetic nephropathy is estimated to be 6 - 16% in SSA. The current dialysis treatment rate is < 20 pmp (and nil in many countries of SSA), with in-center hemodialysis the modality of RRT for the majority. Transplantation is carried out in a few SSA countries: South Africa, Nigeria, Mauritius and Ghana, with most of the transplants being living donor transplants, except in South Africa where the majority are from deceased donors. CONCLUSION:Chronic kidney disease care is especially challenging in SSA, with large numbers of ESRDpatients, inadequate facilities, funding and support.
Authors: Charlotte Osafo; Yemi R Raji; Timothy Olanrewaju; Manmak Mamven; Fatiu Arogundade; Samuel Ajayi; Ifeoma Ulasi; Babatunde Salako; Jacob Plange-Rhule; Yewondwossen Mengistu; S O Mc'Ligeyo; George Moturi; Cheryl A Winkler; Marva M Moxey-Mims; Rebekah S Rasooly; Paul Kimmel; Dwomoa Adu; Akinlolu Ojo; Rulan S Parekh Journal: Kidney Int Date: 2016-07 Impact factor: 10.612
Authors: V Boima; M B Amissah-Arthur; E Yorke; D Dey; Delali Fiagbe; A E Yawson; J Nonvignon; C C Mate-Kole Journal: BMC Nephrol Date: 2021-04-13 Impact factor: 2.388
Authors: A P Doumatey; J Zhou; H Huang; J Adeleye; W Balogun; O Fasanmade; T Johnson; J Oli; G Okafor; A Amoah; B Eghan; K Agyenim-Boateng; J Acheampong; C Adebamowo; A Adeyemo; C N Rotimi Journal: Int J Nephrol Date: 2012-08-22